Supplemental Information or Form
Form LAB 444 (03/12) (MDL-N-25), EXAMINATION FOR MYCOBACTERIUM TUBERCULOSIS DRUG SUSCEPTIBILITY
Performed on Specimens from
California local public health laboratories
Acceptable Sample/Specimen Type for Testing
Minimum Volume Required
Storage & Preservation of Specimen Prior to Shipping
Incubated at 35-37°C (or refrigerated)
Patient’s name, accession number, inoculation or subculture date
Shipping Instructions which Include Specimen Handling Requirements
Ship as infectious substance.
MGIT 960. Drugs tested are amikacin 1.5 µg/ml, moxifloxacin 0.25 µg/ml, capreomycin 3µg/ml, and ethionamide 5µg/ml. If there is resistance to moxifloxacin at 0.25 μg/ml, this predicts resistance to levofloxacin as well. When there is moxifloxacin resistance, a “mini-MIC” is performed, testing with moxifloxacin at 0.5, 1, 2, and 3 μg/ml. If the initial testing shows ethionamide resistance, testing at 5 µg/ml and 10 µg/ml is performed.
7 to 14 days
Interferences & Limitations
Results unattainable because culture submitted is mixed with another mycobacteria (usually Mycobacterium avium complex) or another non-mycobacteria contaminant.
MDL Points of Contact
Mycobacterial Diseases Section (drug susceptibilities) (510) 412-3929 Email: email@example.com
| Conditions of Use